Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 175 results
May 2017
-
Media ReleaseSandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines AgencySandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data…
-
Media ReleaseAt the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become…
March 2017
-
Media ReleaseNovartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasisNew data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Media ReleaseNovartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pauseNew analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and…
-
Media ReleaseNew data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicineSandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…
November 2016
-
Media ReleaseInnovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originatorNo clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1] Innovative study design demonstrates switching between…
-
Media ReleaseNovartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported painCosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]* New data show that with Cosentyx the high…
Pagination
- ‹ Previous page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- › Next page